HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Clinical trials for HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat breast cancer mutation
Disease control CompletedThis early-phase trial tested a new drug, ipatasertib, added to two existing breast cancer medicines (trastuzumab and pertuzumab) in 17 people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation). The main goal was to find the safest dose…
Matched conditions: HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a second round of pertuzumab help fight advanced breast cancer?
Disease control CompletedThis phase 3 trial tested whether giving pertuzumab again, along with trastuzumab and chemotherapy, could help people with HER2-positive advanced breast cancer who had already received pertuzumab before. The study enrolled 226 participants and compared retreatment to standard tra…
Matched conditions: HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Japan Breast Cancer Research Group • Aim: Disease control
Last updated Jun 26, 2026 15:52 UTC